Cargando…

Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies

Background: The current review aimed to pool real-world evidence on the efficacy and toxicity of consolidation durvalumab for stage III unresectable non-small cell lung cancer (NSCLC) after curative chemoradiotherapy. Methods: PubMed, CENTRAL, ScienceDirect, Embase, and Google Scholar were searched...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yatong, Tian, Yumei, Zheng, Li, Sun, Xuelin, Zhao, Zinan, Zheng, Yujing, Tian, Jinhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285075/ https://www.ncbi.nlm.nih.gov/pubmed/37361225 http://dx.doi.org/10.3389/fphar.2023.1103927

Ejemplares similares

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
por: Chu, Chia‐Hsun, et al.
Publicado: (2020)

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
por: Preti, Beatrice T. B., et al.
Publicado: (2023)

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
por: Langberg, Christian Wilhelm, et al.
Publicado: (2023)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone
por: Saad, Akram, et al.
Publicado: (2022)

Three-Dimensional Echocardiography and Coagulation Function Detection in the Prognosis Evaluation of Patients with Acute Myocardial Infarction
por: Zhang, Yatong, et al.
Publicado: (2022)

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study
por: Wang, Chin-Chou, et al.
Publicado: (2021)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
por: Bruni, Alessio, et al.
Publicado: (2021)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy
por: Nam, Jung Hyun, et al.
Publicado: (2023)

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
por: Diamond, Brett H., et al.
Publicado: (2022)

Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
por: Bruni, Alessio, et al.
Publicado: (2021)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
por: Liu, Yufei, et al.
Publicado: (2022)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
por: Shaverdian, Narek, et al.
Publicado: (2020)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
por: Zhang, Qiongwen, et al.
Publicado: (2023)

Real-World Prevalence of Direct Oral Anticoagulant Off-Label Doses in Atrial Fibrillation: An Epidemiological Meta-Analysis
por: Shen, Nan-Nan, et al.
Publicado: (2021)

Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
por: Zheng, Jieling, et al.
Publicado: (2022)

Prevalence of Polypharmacy and Potentially Inappropriate Medications Use in Elderly Chinese Patients: A Systematic Review and Meta-Analysis
por: Tian, Fangyuan, et al.
Publicado: (2022)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
por: Botticella, Angela, et al.
Publicado: (2019)

Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis
por: de Castro, Caroline Tianeze, et al.
Publicado: (2022)

SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhao, Zinan, et al.
Publicado: (2022)

The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer
por: Matsuura, Shun, et al.
Publicado: (2023)

Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: A systematic review and meta-analysis
por: Hou, Liyan, et al.
Publicado: (2023)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Sarcoid-Like Granulomatosis of the Lung Related to Durvalumab After Chemoradiation for Pulmonary Squamous Cell Carcinoma
por: Minami, Seigo, et al.
Publicado: (2023)

Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab
por: Nindra, Udit, et al.
Publicado: (2022)

Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
por: Kishi, Noriko, et al.
Publicado: (2022)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer
por: Sankar, Kamya, et al.
Publicado: (2022)

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
por: Moodie, Travis, et al.
Publicado: (2022)

The Optimal Chinese Herbal Injections for Use With Radiotherapy to Treat Esophageal Cancer: A Systematic Review and Bayesian Network Meta-Analysis
por: Zhang, Dan, et al.
Publicado: (2019)

Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies
por: Qian, Jun, et al.
Publicado: (2021)

Characteristics and Spectrum of Cardiotoxicity Induced by Various Antipsychotics: A Real-World Study From 2015 to 2020 Based on FAERS
por: He, Luyao, et al.
Publicado: (2022)

Enteral Lactoferrin Supplementation for Preventing Sepsis and Necrotizing Enterocolitis in Preterm Infants: A Meta‑Analysis With Trial Sequential Analysis of Randomized Controlled Trials
por: Gao, Ya, et al.
Publicado: (2020)

Antioxidant and Anti-Inflammatory Properties of Hydroxyl Safflower Yellow a in Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials
por: Fu, Shunlian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_60a6m8lcn884uvbchdpgfonesd